Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02058719 · ClinicalTrials.gov registry record
Immunosuppressive Effects of Smoking and HIV-1 on the Development of Lung Disease
A clinical trial, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 210
- Enrollment target
NCT02058719 is a clinical trial that has completed, run by University of Colorado, Denver. The registered enrollment target is 210 participants.
The verdict
NCT02058719 has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 210 participants
- Enrollment target
Study Summary
This study plans to learn more about pulmonary complications of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS). Even though antiretroviral therapy (ART) has dramatically decreased the number of opportunistic infections and deaths in HIV infected patients, pulmonary complications (including chronic obstructive pulmonary disease (COPD) development and pneumonias resulting in decreased lung function) of HIV/AIDS continue to be a major cause of morbidity and mortality in this population. The mechanisms underlying the increased risk of COPD and decreased lung function in HIV infected individuals is not well understand and needs to be studied. The investigators hypothesize that the immunoregulatory consequences and immunosuppressive lung milieu secondary to HIV and cigarette smoke combine to increase the risk of lung infection and injury in HIV infected smokers, hastening the development of COPD. The mechanisms will be directly tested using blood and bronchial alveolar lavage (BAL) cells from smokers and nonsmokers with and without HIV infection.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2014-03 |
| Est. Completion | 2019-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02058719
The ClinicalTrials.gov registry entry for NCT02058719 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02058719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02058719 about?
NCT02058719 is a clinical study titled "Immunosuppressive Effects of Smoking and HIV-1 on the Development of Lung Disease". This study plans to learn more about pulmonary complications of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS). Even though antiretroviral therapy (ART) has dramatically decreased the number of opportunistic infections and deaths in HIV infected patients, pulmonary compli...
What is the current status of trial NCT02058719?
This trial is currently completed. The enrollment target is 210 participants. The study started on 2014-03. Estimated completion is 2019-12.
Who is sponsoring clinical trial NCT02058719?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.